Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cancer drug developer Antisoma has started a Phase II trial evaluating the addition of AS1402 to the endocrine therapy letrozole in post-menopausal women receiving first-line treatment for advanced breast cancer.
Subscribe to our email newsletter
Approximately 110 patients will be randomly assigned to receive either letrozole plus AS1402 or standard treatment with letrozole alone. The safety of the AS1402-letrozole combination will be evaluated and its efficacy compared with that of letrozole alone. Measures of efficacy will include response rates, time to tumor progression, progression-free survival and clinical benefit rate. Final results are expected in 2010.
The Phase II trial builds on a Phase I study in patients with heavily pre-treated breast cancer, which showed that AS1402 monotherapy was well-tolerated and was associated with prolonged stable disease in a number of patients. Hospitals in the US, Russia, Ukraine, Poland and France are taking part in the Phase II study.
Ursula Ney, Antisoma’s COO, said: “Worldwide, over 90,000 women each year receive endocrine treatment for advanced breast cancer, so many patients could benefit from any add-on therapy that improved outcomes in this setting. Our Phase II study rigorously tests the value of adding AS1402 to endocrine treatment and, if positive, will provide a firm basis for progress to a pivotal Phase III trial in breast cancer.”